NutNow you can listen to the Fox News items!
Some patients who take GLP-1 drug loss drugs have been forced to change to a different drug due to a change in insurance coverage, and they are not happy with it.
From July 1, CVS Caremark, one of the largest benefits managers of the United States pharmacy, left Zepbound (Tirzepatide) on his favorite medicine list, replacing him with Wegovy (Semaglutide).
Zepbound, along with his medication against counterparty diabetes, Mounjaro, is made by Eli Lilly, while Wegovy is produced by Novo Nordisk, who also does Ozempic.
CVS Camerk lowes the duty loss of popular weight loss
CVS Caremark blamed the increase in change costs. In a declaration of June 27 on its website, the company said that “medicine manufacturers are solely responsible for setting the price of drugs and have a high cost medication, which makes it difficult for many people to access it.”
In an effort to “lower out -of -pocket medicine prices”, CVS Caremark said he was associated with Novo Nordisk to “significantly increase the access to Wegovy for our members at a more affordable price.”
Some Patients who take GLP-1 drug loss drugs have been forced to change to a different drug due to a change in insurance coverage. (Istock)
“On July 1, 2025, we will do a form action to prefer Wegovy and eliminate Zepbound,” the statement continued. “We are confident that our decision to prefer Wegovy in our commercial staff forms will allow a wider and affordable coverage for weight management medicines, while retaining clinical integrity.”
Dr. Tro Kalayjian, a board -certified doctor who practices Internal Medicine and Obesity based in New York, said that the lack of choice of the patient always adversely affects patients.
The study reveals the main cause of obesity and is not lack of exercise
“Some people do not tolerate certain drugs and be forced to change to a new drug has a clear way to stop progress,” Fox News Digital told. “Forced change disrupts continuity of attention.”
“The drug change is not always perfect; dosage must often be in contact and side effects can reappear.”
Wegovy is a weight loss medicine of the Danish prescription by the Danish Novo Nordisk company. (Michael Siluk/UCG/Universal Image Group through Getty Images)
Many patients who received Caremark letters on change have gone on social media to express their concerns.
“I have just been approved by Zepbound two months ago … I have only been there for two months and I have already dropped by £ 25.8,” a user wrote in Reddit. “I have increased the dose twice since I am now in the third month and I have had little or nothing side effects. It has been working so well for me, I am very nervous to have to change medicines.”
Popular weight loss drugs show new promising power against wearing migraines
Another user wrote, “ CVS has just sent a letter stating that he was no longer covered and that he could go to Wegovy.However, I tried Wegovy before Zepbound and he made me ill. There should be exceptions to this rule. Since I am only using the shot every week, maybe I will pay it through his website. It works for me and I do not want to have the possibility of gaining weight. ”
“It has been working so well for me, I am very nervous to have to change medication.”
CVS Camerk stated in his ad that the patients who previously tried Wegovy and
The “severe or intolerable side effects” or “did not get a sufficient weight loss” may request that an “form of the form” be covered for a drug for a different weight loss.
“You or your supplier will be able to start an exception request, which allows a medical need to be reviewed in case to determine if the coverage of an alternative therapy is adequate depending on your clinical circumstances,” the company said.
Zepbound – along with the medication against counterparty diabetes, Mounjaro, is made by Eli Lilly, based in Indianapolis. (Istock)
Patients may choose to buy Zepbound directly from Eli Lilly, said Kalayjian, but the medication is expensive, with a cost of about $ 300 to $ 500 per month.
“Unfortunately, people are so desperate that they buy versions of Tiktok’s medicine research and social media,” he said.
Click here to get the Fox News app
Kalayjian said that Zepbound is “a little more effective” than Wegovy, as he has an additional mechanism, but both drugs are “very similar” in the results of weight loss.
“There are slightly less nausea and vomiting with Zepbound,” he added.
A recent study found that Tirzepatida achieved a greater weight loss than Semaglutid, and participants spilled about 50 pounds (20.2% of their body weight). (Istock)
In a recent 72 -week clinical trial published in the New England Journal of Medicine, researchers compared the safety and effectiveness of the Tyrzepatida (Zepbound) and the Semagovy (Wegovy).
Click here to register -you are in our health newsletter
The studio found that the Tyrzepatida achieved Greater weight losswith participants who spill approximately 50 pounds (20.2% of their body weight).
The group that takes the semaglutide lost an average of 33 pounds or 13.7% of its initial weight, according to a press statement that summarizes the result of the study.
“The change in drugs is not always perfect; the dosage must often be re -titled and the side effects can reappear,” said an expert. (Istock)
Generally, 32% of people who took Tirzepatida lost at least 25% of their body weight; Semaglutid users lost about 16%.
Tirzepatide users also reported a “greater reduction in the circumference of the waist” than those of the semaglutide.
For more health items, visit www.foxnews.com/health
The side effects reported were very similar to the two drugs, with 44% of people who experience nausea and 25% with abdominal pain.
Fox News Digital contacted Eli Lilly and Novo Nordisk for comments.
#Patients #weight #loss #Zepbound #forced #switch #Wegovy #fall #coverage
Image Source : www.foxnews.com